LEO Pharma Inc. Launches Enhanced Website for Taclonex® Plaque Psoriasis Treatments

Parsippany, NJ – April 27, 2011 – LEO Pharma Inc., a wholly owned U.S. subsidiary of LEO Pharma A/S, makers of Taclonex® brand products, today announced the launch of an enhanced and expanded website at www.taclonex.com. The website offers the most comprehensive information available regarding Taclonex® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Ointment and Taclonex Scalp® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Topical Suspension.

“Increasing numbers of patients turn to the web for information about psoriasis and available treatments,” noted John Koconis, president and chief executive officer at LEO Pharma Inc. “We have enhanced the site so that patients can more easily discover information about Taclonex® brand products, the only once-daily prescription combination therapies for plaque psoriasis on the market.”

Updates to the site include the addition of product information for both Taclonex® Ointment and Taclonex Scalp® and enhanced usability and navigation. Eligible patients can also download a personalized patient savings card for Taclonex® Ointment and/or Taclonex Scalp® prescriptions.

Psoriasis is a non-contagious, chronic disease of the immune system that affects an estimated 125 million people worldwide. According to the National Institutes of Health, more than seven million adult Americans have been diagnosed with psoriasis, of which 80% have plaque psoriasis. Plaque psoriasis generally appears as patches of raised, red skin covered by flaky white buildup of dead skin cells. These patches most often appear on the scalp, knees, elbows and torso, are often itchy and painful, and can crack and bleed.

About Taclonex® Ointment and Taclonex Scalp® Topical Suspension

Taclonex® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Ointment is approved for use on the skin to treat psoriasis vulgaris (plaque psoriasis) in adults 18 years of age and older and should be applied to affected areas once daily for up to 4 weeks. Taclonex Scalp® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Topical Suspension is approved to treat moderate to severe psoriasis vulgaris of the scalp in adults 18 years and older and should be applied to affected areas on the scalp once a day for 2 weeks or until cleared. If the affected area is not cleared, Taclonex Scalp® Topical Suspension may be continued for up to 8 weeks. Do not exceed the recommended weekly dose of 100 grams. Neither product is recommended for use on children.

IMPORTANT SAFETY INFORMATION ABOUT TACLONEX® OINTMENT AND TACLONEX SCALP® TOPICAL SUSPENSION

FOR TOPICAL USE ONLY. Do not use Taclonex® Ointment or Taclonex Scalp® Topical Suspension on your face, under your arms, or on your groin. Do not get either product in your eyes, mouth, or vaginal area. Do not swallow Taclonex® Ointment or Taclonex Scalp® Topical Suspension.

You should not use Taclonex® Ointment or Taclonex Scalp® Topical Suspension if you are allergic to any of their ingredients, have thin skin (atrophy) at the treatment site, have known or suspected calcium metabolism disorders (too much or too little calcium in your blood or urine), have erythrodermic, exfoliative, or pustular psoriasis, or have severe kidney or severe liver disease. Avoid excessive exposure to either natural or artificial sunlight if you apply Taclonex® Ointment to exposed portions of your body or use Taclonex Scalp® Topical Suspension. Tell your doctor if you have a skin infection, are getting
phototherapy treatments for your psoriasis, are pregnant, or planning to become pregnant, or are breastfeeding. Also tell your doctor about other medicines you are taking, especially other corticosteroids, products containing calcipotriene, or medicines for your psoriasis.

Taclonex® Ointment and Taclonex Scalp® Topical Suspension each may cause serious side effects if you use too much, use them for too long, or use them with other medicines that contain corticosteroids or calcipotriene. Taclonex® Ointment and Taclonex Scalp® Topical Suspension contain the same medicine to treat psoriasis vulgaris. If you use both medicines to treat your psoriasis vulgaris, be sure to follow your doctor’s directions carefully so that you do not use too much of one or both of these medicines. Taclonex® Ointment and Taclonex Scalp® Topical Suspension can pass through your skin. **Serious side effects may include too much calcium in your blood or urine or adrenal gland problems.** Your doctor may do special blood and urine tests to check your calcium levels and adrenal gland function while you are using Taclonex® Ointment or Taclonex Scalp® Topical Suspension.

The most common side effects of Taclonex® Ointment are itching and rash. Other less common side effects include redness of the skin, inflamed hair pores (folliculitis), skin irritation, skin burning, change of skin color (at the site of application), rash with pus-filled papules, thinning of the skin, and swollen fine blood vessels (this makes your skin appear red at the site of application).

The most common side effects of Taclonex Scalp® Topical Suspension are inflamed hair pores (folliculitis) and burning sensation of the skin. Other side effects include itching, worsening of psoriasis, redness of the skin, and skin pain or irritation.

Please see the full Prescribing Information at www.taclonex.com.